135 related articles for article (PubMed ID: 34737092)
1. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes.
Wang L; Scott FI; Boursi B; Reiss KA; Williams S; Glick H; Yang YX
Clin Gastroenterol Hepatol; 2022 Sep; 20(9):1997-2004.e7. PubMed ID: 34737092
[TBL] [Abstract][Full Text] [Related]
2. Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.
Schwartz NRM; Matrisian LM; Shrader EE; Feng Z; Chari S; Roth JA
J Natl Compr Canc Netw; 2021 Jun; 20(5):451-459. PubMed ID: 34153945
[TBL] [Abstract][Full Text] [Related]
3. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.
Lewis D; Wong WWL; Lipscomb J; Horton S
Pharmacoeconomics; 2024 Apr; 42(4):393-407. PubMed ID: 38150120
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract][Full Text] [Related]
5. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma.
Chari ST; Maitra A; Matrisian LM; Shrader EE; Wu BU; Kambadakone A; Zhao YQ; Kenner B; Rinaudo JAS; Srivastava S; Huang Y; Feng Z;
Contemp Clin Trials; 2022 Feb; 113():106659. PubMed ID: 34954100
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of MicroRNA for Pancreatic Cancer Screening in Patients With Diabetes.
Kowada A
Pancreas; 2022 Sep; 51(8):1019-1028. PubMed ID: 36607949
[TBL] [Abstract][Full Text] [Related]
9. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer.
Takikawa T; Kikuta K; Kume K; Hamada S; Miura S; Yoshida N; Hongo S; Tanaka Y; Matsumoto R; Sano T; Ikeda M; Iseki M; Unno M; Masamune A
Tohoku J Exp Med; 2020 Dec; 252(4):353-364. PubMed ID: 33342915
[TBL] [Abstract][Full Text] [Related]
10. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.
Joergensen MT; Gerdes AM; Sorensen J; Schaffalitzky de Muckadell O; Mortensen MB
Pancreatology; 2016; 16(4):584-92. PubMed ID: 27090585
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat AA; Nelson R; Au T; Biskupiak J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Ingram MA; Lauren BN; Pumpalova Y; Park J; Lim F; Bates SE; Kastrinos F; Manji GA; Kong CY; Hur C
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1565. PubMed ID: 35122419
[TBL] [Abstract][Full Text] [Related]
14. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
16. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma.
Kumar S; Saumoy M; Oh A; Schneider Y; Brand RE; Chak A; Ginsberg GG; Kochman ML; Canto MI; Goggins MG; Hur C; Kastrinos F; Katona BW; Rustgi AK
Pancreas; 2021 Jul; 50(6):807-814. PubMed ID: 34149034
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
18. Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes.
Balasenthil S; Liu S; Dai J; Bamlet WR; Petersen G; Chari ST; Maitra A; Chen N; Sen S; McNeill Killary A
Clin Chim Acta; 2023 Nov; 551():117567. PubMed ID: 37774897
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis.
Kapoor R; So JBY; Zhu F; Too HP; Yeoh KG; Yoong JS
Value Health; 2020 Sep; 23(9):1171-1179. PubMed ID: 32940235
[TBL] [Abstract][Full Text] [Related]
20. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M
Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
